These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29741401)

  • 21. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
    Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
    EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer's Disease: The Relationship with Other Atherosclerosis Risk Factors.
    Macesic M; Lalic NM; Kostic VS; Jotic A; Lalic K; Stefanova E; Milicic T; Lukic L; Gajovic JS; Krako N
    Curr Vasc Pharmacol; 2017; 15(2):158-166. PubMed ID: 27599805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Non-Ceruloplasmin Non-Albumin Copper Elevation in Mild Cognitive Impairment and Dementia due to Alzheimer's Disease: A Case Control Study.
    Rozzini L; Lanfranchi F; Pilotto A; Catalani S; Gilberti ME; Paganelli M; Apostoli P; Padovani A
    J Alzheimers Dis; 2018; 61(3):907-912. PubMed ID: 29332043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing.
    Hare DJ; Faux NG; Roberts BR; Volitakis I; Martins RN; Bush AI
    Metallomics; 2016 Jun; 8(6):628-32. PubMed ID: 26962965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease and Mild Cognitive Impairment: a Comprehensive Systematic Review and Meta-analysis.
    Kim BY; Lee SH; Graham PL; Angelucci F; Lucia A; Pareja-Galeano H; Leyhe T; Turana Y; Lee IR; Yoon JH; Shin JI
    Mol Neurobiol; 2017 Nov; 54(9):7297-7311. PubMed ID: 27815832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.
    Han P; Caselli RJ; Baxter L; Serrano G; Yin J; Beach TG; Reiman EM; Shi J
    JAMA Neurol; 2015 Mar; 72(3):333-9. PubMed ID: 25599520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study.
    Costa AC; Joaquim HPG; Forlenza OV; Gattaz WF; Talib LL
    Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):483-488. PubMed ID: 31218445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer's Disease.
    Benussi L; Ghidoni R; Dal Piaz F; Binetti G; Di Iorio G; Abrescia P
    J Alzheimers Dis; 2017; 56(2):825-833. PubMed ID: 27983556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts.
    Muenchhoff J; Poljak A; Song F; Raftery M; Brodaty H; Duncan M; McEvoy M; Attia J; Schofield PW; Sachdev PS
    J Alzheimers Dis; 2015; 43(4):1355-73. PubMed ID: 25159666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia.
    Dukic L; Simundic AM; Martinic-Popovic I; Kackov S; Diamandis A; Begcevic I; Diamandis EP
    Clin Biochem; 2016 Feb; 49(3):213-8. PubMed ID: 26515085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease.
    Llano DA; Devanarayan V; Simon AJ;
    Alzheimer Dis Assoc Disord; 2013; 27(3):233-43. PubMed ID: 23023094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Peptidome Technology for the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease by Selected Reaction Monitoring.
    Fukui Y; Tadokoro K; Hamada M; Asada K; Lee LJ; Tachiki H; Morihara R; Abe K; Yamashita T
    J Alzheimers Dis; 2024; 100(1):219-228. PubMed ID: 38848173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty.
    Ruan Q; D'Onofrio G; Sancarlo D; Greco A; Yu Z
    Mol Med Rep; 2016 Oct; 14(4):3184-98. PubMed ID: 27511317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease.
    Oh J; Lee HJ; Song JH; Park SI; Kim H
    Exp Gerontol; 2014 Dec; 60():87-91. PubMed ID: 25304332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipidomic alterations in lipoproteins of patients with mild cognitive impairment and Alzheimer's disease by asymmetrical flow field-flow fractionation and nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry.
    Kim SH; Yang JS; Lee JC; Lee JY; Lee JY; Kim E; Moon MH
    J Chromatogr A; 2018 Sep; 1568():91-100. PubMed ID: 30007793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphocytic mitochondrial aconitase activity is reduced in Alzheimer's disease and mild cognitive impairment.
    Mangialasche F; Baglioni M; Cecchetti R; Kivipelto M; Ruggiero C; Piobbico D; Kussmaul L; Monastero R; Brancorsini S; Mecocci P
    J Alzheimers Dis; 2015; 44(2):649-60. PubMed ID: 25322927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
    Kvartsberg H; Duits FH; Ingelsson M; Andreasen N; Öhrfelt A; Andersson K; Brinkmalm G; Lannfelt L; Minthon L; Hansson O; Andreasson U; Teunissen CE; Scheltens P; Van der Flier WM; Zetterberg H; Portelius E; Blennow K
    Alzheimers Dement; 2015 Oct; 11(10):1180-90. PubMed ID: 25533203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.